Cargando…

Observed Changes in Natural Killer and T cell Phenotypes with Evaluation of Immune Outcome in a Longitudinal Cohort Following Sofosbuvir-Based Therapy for Chronic Hepatitis C Infection

BACKGROUND: Chronic hepatitis C virus (HCV) infection diminishes immune function through cell exhaustion and repertoire alteration. Direct acting antiviral (DAA)-based therapy can restore immune cell subset function and reduce exhaustion states. However, the extent of immune modulation following DAA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stevenson, Timothy J, Barbour, Youssef, McMahon, Brian J, Townshend-Bulson, Lisa, Hewitt, Annette M, Espera, Hannah G F, Homan, Chriss, Holck, Peter, Luna, Sarah V, Knall, Cindy, Simons, Brenna C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6589029/ https://www.ncbi.nlm.nih.gov/pubmed/31249845 http://dx.doi.org/10.1093/ofid/ofz223

Ejemplares similares

The Alaska Native/American Indian experience of hepatitis C treatment with sofosbuvir-based direct-acting antivirals
por: Townshend-Bulson, Lisa, et al.
Publicado: (2021)

Results of interferon-based treatments in Alaska Native and American Indian population with chronic hepatitis C
por: Livingston, Stephen E., et al.
Publicado: (2016)

Autoimmune hepatitis and overlap syndrome among Alaska Native people: Prevalence, clinical characteristics, and remission
por: Johnston, Janet M., et al.
Publicado: (2023)

Treatment eligibility in Alaska Native and American Indian persons with hepatitis C virus infection
por: Livingston, Stephen E., et al.
Publicado: (2012)

Ledipasvir and Sofosbuvir in the Treatment of Early Hepatitis C Virus Infection in HIV-Infected Men
por: Palaniswami, Paari M, et al.
Publicado: (2018)

HIV Coinfection Predicts Failure of Ledipasvir/Sofosbuvir in Treatment-Naïve Noncirrhotic Patients With HCV Genotype 1
por: Berenguer, Juan, et al.
Publicado: (2019)

Minimal Compared With Standard Monitoring During Sofosbuvir-Based Hepatitis C Treatment: A Randomized Controlled Trial
por: Davis, J S, et al.
Publicado: (2020)

Ledipasvir/Sofosbuvir for Patients Coinfected With Chronic Hepatitis C and Hepatitis B in Taiwan: Follow-up at 108 Weeks Posttreatment
por: Liu, Chun Jen, et al.
Publicado: (2021)

Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 Studies
por: Grebely, Jason, et al.
Publicado: (2018)

Evaluation of Safety and Effectiveness of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Switch Followed by Ledipasvir/Sofosbuvir HCV Therapy in HIV–HCV Coinfection
por: Doyle, Mary-Anne, et al.
Publicado: (2019)

Real-world Effectiveness of Sofosbuvir/Velpatasvir for Treatment of Chronic Hepatitis C in British Columbia, Canada: A Population-Based Cohort Study
por: Wilton, James, et al.
Publicado: (2020)

High Cure Rates for Hepatitis C Virus Genotype 6 in Advanced Liver Fibrosis With 12 Weeks Sofosbuvir and Daclatasvir: The Vietnam SEARCH Study
por: Flower, Barnaby, et al.
Publicado: (2021)

Attacking the public health crisis of hepatocellular carcinoma at its roots
por: Lee, Hannah M., et al.
Publicado: (2023)

Early and late changes in natural killer cells in response to ledipasvir/sofosbuvir treatment
por: Golden‐Mason, Lucy, et al.
Publicado: (2018)

In Utero Activation of Natural Killer Cells in Congenital Cytomegalovirus Infection
por: Vaaben, Anna V, et al.
Publicado: (2022)

Hyperinflammatory Syndrome, Natural Killer Cell Function, and Genetic Polymorphisms in the Pathogenesis of Severe Dengue( )
por: Vuong, Nguyen Lam, et al.
Publicado: (2022)

Sofosbuvir and daclatasvir
por: Hessel, Marleen H. M., et al.
Publicado: (2016)

Role of the Killer Immunoglobulin-like Receptor and Human Leukocyte Antigen I Complex Polymorphisms in Kaposi Sarcoma–Associated Herpesvirus Infection
por: Zhang, Xin, et al.
Publicado: (2023)

Balancing Statistical Power and Risk in HIV Cure Clinical Trial Design
por: Lau, Jillian S Y, et al.
Publicado: (2022)

Fundamental trends within falling match rates: Insights from the past decade of Canadian residency matching data
por: Zeng, Andy G.X., et al.
Publicado: (2020)

Genetic Diversity of Near Genome-Wide Hepatitis C Virus Sequences during Chronic Infection: Evidence for Protein Structural Conservation Over Time
por: Li, Hui, et al.
Publicado: (2011)

EBV-Encoded MicroRNA-BART17-3p Targets DDX3X and Promotes EBV Infection in EBV-Associated T/Natural Killer–Cell Lymphoproliferative Diseases
por: Jin, Jin, et al.
Publicado: (2023)

HIV-1 Infection Does Not Change Disease Course or Inflammatory Pattern of SARS-CoV-2-Infected Patients Presenting at a Large Urban Medical Center in New York City
por: Laracy, Justin, et al.
Publicado: (2021)

Brief report on the effect of providing single versus assorted brand name condoms to hospital patients: a descriptive study
por: Williams, James L, et al.
Publicado: (2001)

Observational Study Evaluating the Seroprotection of HepB-alum Vaccine and HepB-CpG Vaccine in People With HIV
por: Reilly-Evans, Brenna, et al.
Publicado: (2023)

Recovery of natural killer cells is mainly in post-treatment period in chronic hepatitis C patients treated with sofosbuvir plus ledipasvir
por: Wang, Xiao-Xiao, et al.
Publicado: (2018)

Assessment of Virological Contributions to COVID-19 Outcomes in a Longitudinal Cohort of Hospitalized Adults
por: Simons, Lacy M, et al.
Publicado: (2022)

Antibody-Dependent Natural Killer Cell Activation After Ebola Vaccination
por: Wagstaffe, Helen R, et al.
Publicado: (2019)

Elevated Carbon Monoxide to Carbon Dioxide Ratio in the Exhaled Breath of Mice Treated With a Single Dose of Lipopolysaccharide
por: Langeroudi, Arash Ghalyanchi, et al.
Publicado: (2014)

Statewide Longitudinal Trends in Transmitted HIV-1 Drug Resistance in Rhode Island, USA
por: Novitsky, Vlad, et al.
Publicado: (2021)

Longitudinal Analysis of SARS-CoV-2 Vaccine Breakthrough Infections Reveals Limited Infectious Virus Shedding and Restricted Tissue Distribution
por: Ke, Ruian, et al.
Publicado: (2022)

Comparative Antiviral Efficacy of Generic Sofosbuvir versus Brand Name Sofosbuvir with Ribavirin for the Treatment of Hepatitis C
por: Tang, L., et al.
Publicado: (2018)

Effectiveness of Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in People Who Inject Drugs and/or Those in Opioid Agonist Therapy
por: Janjua, Naveed Z., et al.
Publicado: (2019)

Assessment of Kidney Injury as a Severity Criteria for Clostridioides Difficile Infection
por: Carlson, Travis J, et al.
Publicado: (2020)

Sofosbuvir: A Potential Treatment for Ebola
por: Reznik, Sandra E., et al.
Publicado: (2018)

Sofosbuvir/velpatasvir/voxilaprevir for hepatitis C
Publicado: (2019)

Potential Use of Sofosbuvir in the Prophylaxis for Rabies
por: Reznik, Sandra E., et al.
Publicado: (2020)

Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus
por: McEwan, Phil, et al.
Publicado: (2017)

Incidence of Hepatocellular Carcinoma after Treatment with Sofosbuvir-Based or Sofosbuvir-Free Regimens in Patients with Chronic Hepatitis C
por: Ogawa, Eiichi, et al.
Publicado: (2020)

Sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir: novel treatment options for naïve and previously treated hepatitis C infection
por: Shin, Hyun Phil
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ho2ihc7oo3p6up25fkdvdehs86